Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Catalyst Pharmaceuticals� dense biotech filings can feel like wading through clinical-trial data, patent tables, and risk factors that stretch for hundreds of pages. Investors searching for “Catalyst Pharmaceuticals SEC filings explained simply� or wondering how Firdapse® revenue moves the needle quickly discover the documents are anything but short. That’s where Stock Titan steps in.
Our AI-powered engine ingests every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR, then serves plain-English answers to questions you actually ask: “Catalyst Pharmaceuticals quarterly earnings report 10-Q filing,� “Catalyst Pharmaceuticals proxy statement executive compensation,� or “Catalyst Pharmaceuticals insider trading Form 4 transactions.� Interactive dashboards display “Catalyst Pharmaceuticals Form 4 insider transactions real-time,� while a single view of “Catalyst Pharmaceuticals executive stock transactions Form 4� reveals buying or selling trends before markets react. The platform’s narrative threads drug-sales shifts, R&D spend, and milestone payments into context you can act on.
Because Catalyst’s growth relies heavily on Firdapse® exclusivity and a focused rare-disease pipeline, even a single disclosure can reshape forecasts. Our summaries flag clinical-trial updates, FDA designations, and royalty agreements—“Catalyst Pharmaceuticals 8-K material events explained� without legal jargon. Dive deeper with “Catalyst Pharmaceuticals annual report 10-K simplified,� or launch an “understanding Catalyst Pharmaceuticals SEC documents with AI� walkthrough that pinpoints where orphan-drug incentives surface in the footnotes. Finally, AI-driven charts turn raw numbers into a “Catalyst Pharmaceuticals earnings report filing analysis,� clarifying revenue concentration, cash runway, and dilution risk—no white coat required.
Daniel J. Curran, a director of Catalyst Pharmaceuticals (CPRX), reports no direct common stock ownership and holds options to acquire 40,000 shares at an exercise price of $21.12. The options vest in three annual tranches beginning August 1, 2026 and expire on August 1, 2032, creating multi-year equity alignment with the company.
Period: Quarterly report for Catalyst Pharmaceuticals, Inc. (CPRX) for the six months ended June 30, 2025.
Key financials: Total revenues $287,984 thousand; product revenue $287,940 thousand; operating income $129,665 thousand; net income $108,845 thousand; diluted EPS $0.86; cash and cash equivalents $652,800 thousand; total assets $971,915 thousand as of June 30, 2025.
Product mix and material items: FIRDAPSE $168,576 thousand, FYCOMPA $69,959 thousand, AGAMREE $49,405 thousand for the six months ended June 30, 2025. Customer A accounted for 75.3% of net product revenue for the six months ended June 30, 2025. Company states it has sufficient funds for at least 12 months and completed a public offering on January 9, 2024 raising net proceeds of approximately $140.7 million.
FAQ
What is the current stock price of Catalyst Pharmaceuticals (CPRX)?
What is the market cap of Catalyst Pharmaceuticals (CPRX)?
